Synthetic Canines: Warhound Secures $200M to Engineer Military Dogs

The United States military currently relies on foreign sources for a majority of its working dogs, a dependency that a new biotech venture seeks to eliminate through genetic engineering. On Thursday, Warhound emerged from stealth mode with $200 million in funding, valuing the company at $1.2 billion. The new enterprise is backed by investors including Sequoia, 8VC, Corner Ventures, and In-Q-Tel, a venture firm supported by U.S. intelligence agencies.

The concept for Warhound originated from a conversation between Ben Lamm of Colossal Biosciences and Palmer Luckey of Anduril at a conference roughly a year ago. Luckey expressed a desire for improved support for military canines, prompting Lamm to investigate the breeding practices of working dogs. Lamm discovered that many dogs fail training due to inherited health issues, such as poor eyesight, cancer susceptibility, hip dysplasia, and muscle atrophy. This research led to the formation of the company, which aims to address these vulnerabilities through advanced biotechnology.

Warhound’s approach involves editing the genes of top-performing breeds, specifically the Belgian Malinois and German Shepherd. The team has established a biobank using cell lines from these dogs. By adding beneficial genes and removing those associated with health problems, the company intends to create a new type of canine optimized for speed, agility, and olfactory sensitivity. These engineered dogs are designed for tasks that are hazardous for humans or difficult for machines, such as bomb detection and search operations.

Anduril will provide the technological hardware and software to complement the biological enhancements. This includes protection vests and goggles equipped with data sensors that transmit information to handlers, improving situational awareness. Lamm described this as adding capabilities on top of the dog rather than inside it. The goal is to make the animals safer and more effective, which in turn protects their human handlers. Luckey serves as a partner in the venture but holds no equity, while Colossal owns a stake and licenses its technology to the new firm.

Colossal Biosciences, known for its de-extinction projects involving animals like the dodo and mammoth, is using AI and gene cloning techniques to support Warhound. The company’s sister firm, Viagen, will handle the cloning process, a method already used in endangered species programs. The first batch of dogs is scheduled for cloning and incubation soon, with births expected early next year. Service deployment is targeted to begin within two years.

The company has briefed various government groups and plans to sell to the Department of Defense, military service branches, police forces, and first responders. Pricing remains undetermined. To ensure ethical standards, Warhound is working under the guidance of the American Humane Society to certify its training program. The society stated that it looks forward to ensuring the animals are treated humanely. Additionally, retired dogs from the program may enter the society’s reunification program, which helps find homes for former military canines.

Each dog will undergo standard military working dog training and be managed by its purchaser. Lamm noted that the enhancements aim to improve longevity and performance, addressing the dwindling domestic supply of fit working dogs. The initiative represents a significant shift in how the U.S. prepares its canine assets for high-stakes operations.